BCAB - BioAtla, Inc.
4.59
-0.320 -6.972%
Share volume: 27,975
Last Updated: 04-17-2026
Pharmaceutical Products/Biological Products, Except Diagnostic Substances:
0.23%
PREVIOUS CLOSE
CHG
CHG%
$4.91
-0.32
-0.07%
View ratios
| Fiscal Date | 03-31-2024 | 06-30-2024 | 09-30-2024 | 12-31-2024 | 03-31-2025 | 09-30-2025 | |
|---|---|---|---|---|---|---|---|
| Fiscal Quarter | Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q3 2025 | |
| Report Date | 05-14-2024 | 08-08-2024 | 11-07-2024 | 03-27-2025 | 05-06-2025 | 11-13-2025 | |
| Total revenue | 0.000 | 0.000 | 11.000 M | 0.000 | 0.000 | 0.000 | |
| Cost of revenue | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Gross profit | 0.000 | 0.000 | 11.000 M | 0.000 | 0.000 | 0.000 | |
| nan% | inf% | -100.00% | nan% | ||||
| Operating expenses | 24.457 M | 21.972 M | 22.270 M | 16.244 M | 17.614 M | 13.789 M | |
| Selling general and admin | 5.605 M | 5.774 M | 5.875 M | 4.594 M | 5.259 M | 4.250 M | |
| Research and development | 18.852 M | 16.198 M | 16.395 M | 11.650 M | 12.355 M | 9.539 M | |
| Total expenses | 24.457 M | 21.972 M | 22.270 M | 16.244 M | 17.614 M | 13.789 M | |
| -10.16% | 1.36% | -27.06% | 8.43% | -21.72% | |||
| Operating income | -24.457 M | -21.972 M | -11.270 M | -16.244 M | -17.614 M | -13.789 M | |
| Ebit | -24.457 M | -21.972 M | -11.278 M | -15.438 M | -15.734 M | -15.908 M | |
| Pretax income | -23.234 M | -21.072 M | -10.586 M | -14.884 M | -15.334 M | -15.775 M | |
| -9.31% | -49.76% | 40.60% | 3.02% | 2.88% | |||
| Income tax | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income basic | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Net income | -23.234 M | -21.072 M | -10.586 M | -14.884 M | -15.334 M | -15.778 M | |
| 9.31% | 49.76% | -40.60% | -3.02% | -2.90% |